Pharos I&Bt

Pharos iBio is a South Korean biotechnology company specializing in AI-driven drug discovery and development for rare and intractable diseases. The company utilizes its proprietary "Chemiverse" platform, which integrates big data and deep learning algorithms to accelerate the identification of novel small molecule candidates. Its lead program, PHI-101, is a potent FLT3 inhibitor currently in Phase 1b clinical trials for relapsed or refractory acute myeloid leukemia. Pharos iBio's pipeline also includes candidates targeting various solid tumors, including melanoma and ovarian cancer, through multi-target inhibition strategies. The company is listed on the KOSDAQ exchange and maintains a global presence with a subsidiary in the United States. Pharos iBio continues to expand its portfolio by leveraging AI to optimize lead generation and clinical success rates.